We have demonstrated that blockade of tumor-derived FGF19/FGFR4 signaling represents a promoting therapeutic strategy to preferentially target FGF19-driven HNSCC [25]. The gene discussed is FGF19; the disease is head and neck squamous cell carcinoma.